首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1535701

多形性膠質母細胞瘤治療市場- 按治療（手術、放射、標靶、化療、免疫療法）、藥物類別（替莫唑胺、貝伐單抗、洛莫司汀）、劑型（口服、腸胃外）、性別、最終用途- 全球預測（2024 - 2032）

Glioblastoma Multiforme Treatment Market - By Treatment (Surgery, Radiation, Targeted, Chemotherapy, Immunotherapy), Drug Class (Temozolomide, Bevacizumab, Lomustine), Dosage Form (Oral, Parenteral), Gender, End-use - Global Forecast (2024 - 2032)

出版日期: 2024年06月13日 | 出版商:

Global Market Insights Inc. | 英文 215 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於研究機構之間的合作關係不斷增加以及醫學研究的進步，2024年至2032年全球多形性膠質母細胞瘤治療市場規模將創下8.6%的複合年成長率。

持續的合作努力正在導致創新療法的開發並改進現有療法，以應對侵襲性腦腫瘤的挑戰。研究人員也共同努力，整合資源和專業知識，從而找到更有效的膠質母細胞瘤治療方法。例如，2023 年2 月，argTex 與IAG 合作，應用人工智慧評估一種新型臨床候選藥物對多形性膠質母細胞瘤患者的效果，以加強治療評估並推進針對具有挑戰性的腦腫瘤的治療選擇。

市場分為治療、藥物類別、劑型、性別、最終用途和地區。

在治療方面，到 2032 年，多形性膠質母細胞瘤治療行業的化療部分將經歷顯著的成長。正在進行的研究正在幫助最佳化化療方案，以提高療效並最大限度地減少副作用。越來越多的努力致力於開發更有針對性的藥物，並將化療與放射和免疫療法等其他治療方法相結合，以實現更好的患者治療效果並延長存活率。

按性別分類，預計2024 年至2032 年，女性多形性膠質母細胞瘤治療市場價值將上升，原因是滿足女性患者特定需求的需求不斷增加，同時考慮到疾病進展和治療反應中的性別差異。正在進行的研究重點是膠質母細胞瘤如何獨特地影響女性，並相應地調整治療方法。此外，治療計劃與標靶治療和個人化方法相結合，以改善女性患者的治療結果。

從區域來看，在癌症研究資金增加以及政府和監管措施支持的推動下，歐洲多形性膠質母細胞瘤治療產業規模預計將在 2024 年至 2032 年間強勁成長。研究團隊正在利用額外的資金來探索新的治療方法並增強現有的療法。各國政府和監管機構正在提供資源和簡化流程，以加速創新療法的發展。支持措施的綜合影響將改變整個歐洲治療這種侵襲性腦腫瘤的方法。

產業生態系統分析
產業影響力
- 成長動力
  - 膠質母細胞瘤的發生率增加
  - 提高疾病意識和早期診斷
  - 研發活動數量增加
- 產業陷阱與挑戰
  - 即使治療後膠質母細胞瘤的復發率也很高
  - 治療費用高
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按處理方式，2021 - 2032 年

主要趨勢
手術
放射治療
化療
標靶治療
腫瘤治療現場治療
免疫療法

第 6 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
替莫唑胺
貝伐珠單抗
洛莫司汀
卡莫司汀晶圓

第 7 章：市場估計與預測：按劑型，2021 - 2032

主要趨勢
口服
注射用

第 8 章：市場估計與預測：按性別分類，2021 - 2032 年

主要趨勢
男性
女性

第 9 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
癌症治療中心
門診手術中心
其他最終用戶

第 10 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Amgen Inc.
Amneal Pharmaceuticals
Curtana Pharmaceuticals
Denovo Biopharma
Eisai Co. Ltd. (Gliadel)
F. Hoffmann La Roche Ltd (Genetech USA)
Karyopharm Therapeutics
Merck & Co. Inc.
Novocure GmbH
Pfizer, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries

簡介目錄

Product Code: 9866

Global Glioblastoma Multiforme Treatment Market size will record 8.6% CAGR from 2024 to 2032, due to increasing partnerships among research institutions along with advancements in medical research.

The ongoing collaborative efforts are leading to the development of innovative therapies and improving existing treatments to address the challenges of the aggressive brain tumor. Researchers are also working together to combine resources and expertise, leading to more effective approaches in managing glioblastoma. For instance, in February 2023, argTex partnered with IAG to apply AI in evaluating the effects of a novel clinical candidate for glioblastoma multiforme patients to enhance treatment assessment and advance therapeutic options for the challenging brain tumor.

The market is segregated into treatment, drug class, dosage form, gender, end-use, and region.

In terms of treatment, the chemotherapy segment in the glioblastoma multiforme treatment industry is set to experience growth at a significant rate through 2032. This is due to the rising prominence of chemotherapy in targeting the dividing cancer cells to slow the tumor growth. Ongoing research is helping in optimizing chemotherapy regimens to enhance effectiveness and minimize side effects. Increasing efforts are directed towards developing more targeted drugs and combining chemotherapy with other treatments like radiation and immunotherapy to achieve better patient outcomes and extend survival rates.

By gender, the glioblastoma multiforme treatment market value from the female segment is projected to rise from 2024 to 2032, fueled by the increasing need to address the specific needs of female patients while considering gender differences in disease progression and treatment response. Ongoing research is focusing on how glioblastoma affects women uniquely and tailoring therapies accordingly. Moreover, treatment plans are integrated with targeted therapies and personalized approaches to improve outcomes for female patients.

Regionally, the Europe glioblastoma multiforme treatment industry size is projected to depict robust growth between 2024 and 2032, driven by increasing funding for cancer research along with supportive government and regulatory initiatives. Research teams are utilizing additional funding to explore new treatment approaches and enhance existing therapies. Governments and regulatory bodies are providing resources and streamlined processes to accelerate the development of innovative treatments. The combined impacts of the supportive measures will transform the approach to treating this aggressive brain tumor across Europe.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of glioblastoma
  - 3.2.1.2 Rising awareness and early diagnosis of disease
  - 3.2.1.3 Increase in the number of R&D activities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High recurrence rate of glioblastoma even after treatment
  - 3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Surgery
5.3 Radiation therapy
5.4 Chemotherapy
5.5 Targeted therapy
5.6 Tumor treating field therapy
5.7 Immunotherapy

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Temozolomide
6.3 Bevacizumab
6.4 Lomustine
6.5 Carmustine wafers

Chapter 7 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Oral
7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 Male
8.3 Female

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

9.1 Key trends
9.2 Hospitals
9.3 Cancer treatment centers
9.4 Ambulatory surgical centers
9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa